Viracta Therapeutics Inc logo

Viracta Therapeutics Inc Share Price Today (NASDAQ: VIRX)

Viracta Therapeutics Inc share price is $0 & ₹0.00 as on 3 Feb 2025 IST

▲

-0.04

(-100%)

Market is closed - opens 7 PM, 14 Jul 2025

Bell Icon

The stock has been delisted from the stock exchange on 4 Feb 2025

View live Viracta Therapeutics Inc share price in Dollar and Rupees. Guide to invest in Viracta Therapeutics Inc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Viracta Therapeutics Inc, along with analyst recommendations, forecasts, and comprehensive financials.

Viracta Therapeutics Inc (VIRX) Key Statistics

in dollars & INR

Previous Close
$0.0352
Open
$0.0325
Market Capitalization
$3.1M
Today's Volume
$1.9M
Revenue TTM
$0.0
EBITDA
$-49.0M
Earnings Per Share (EPS)
$-1.1
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-208.67%

How to invest in Viracta Therapeutics Inc Stock (VIRX) from India?

It is very easy for Indian residents to invest directly in Viracta Therapeutics Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Viracta Therapeutics Inc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Viracta Therapeutics Inc or VIRX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Viracta Therapeutics Inc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Viracta Therapeutics Inc shares which would translate to null fractional shares of Viracta Therapeutics Inc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Viracta Therapeutics Inc, in just a few clicks!

Global Institutional Holdings in Viracta Therapeutics Inc

  • Citadel Advisors Llc

    3.83%

  • Vanguard Group Inc

    2.40%

  • Samsara BioCapital, LLC

    1.74%

  • Stonepine Capital Management Llc

    1.26%

  • LAURION CAPITAL MANAGEMENT LP

    0.84%

  • Aisling Capital Management LP

    0.73%

Analyst Recommendation on Viracta Therapeutics Inc

Rating
Trend

Buy

    90%Buy

    10%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for Viracta Therapeutics Inc(by analysts ranked 0 to 5 stars)

About Viracta Therapeutics Inc

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Organization
Viracta Therapeutics Inc
Employees
40
CEO
Mr. Mark Andrew Rothera
Industry
Miscellaneous

Management People of Viracta Therapeutics Inc

NameTitle
Mr. Mark Andrew Rothera
CEO, President & Director
Dr. Darrel P. Cohen M.D., Ph.D.
Chief Medical Officer
Dr. Susan Perrine M.D.
Scientific Founder and Consultant
Dr. Ronald J. Berenson M.D.
Co-Founder and Consultant
Mr. George Hillman
Co-Founder
Dr. Thalia Papayannopoulou M.D.
Co-Founder
Dr. Robert M. Williams Ph.D.
Co-Founder
Dr. Douglas V. Faller M.D., Ph.D.
Scientific Founder & Chairman of Scientific Advisory Board
Mr. Michael Eric Faerm
Chief Financial Officer
Dr. Ayman El-Guindy
Chief Scientific Officer

Important FAQs about investing in VIRX Stock from India :

Can Indians buy Viracta Therapeutics Inc shares?

Yes, Indians can invest in the Viracta Therapeutics Inc (VIRX) from India.

With INDmoney, you can buy Viracta Therapeutics Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Viracta Therapeutics Inc at zero transaction cost.

How can I buy Viracta Therapeutics Inc shares from India?

It is very easy to buy Viracta Therapeutics Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Viracta Therapeutics Inc (VIRX) be purchased?

Yes, you can buy fractional shares of Viracta Therapeutics Inc with INDmoney app.

What are the documents required to start investing in Viracta Therapeutics Inc stocks?

To start investing in Viracta Therapeutics Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Viracta Therapeutics Inc?

Today's market capitalisation of Viracta Therapeutics Inc VIRX is 3.1M

Who is the Chief Executive Officer (CEO) of Viracta Therapeutics Inc ?

Mr. Mark Andrew Rothera is the current Chief Executive Officer (CEO) of Viracta Therapeutics Inc.